文献速递神经免疫

晚发型多发性硬化疾病修饰治疗的应用

Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple Sclerosis.
PubMed 文献 · Neurology · 2025-07-16

本研究纳入881例55岁后起病的复发缓解型多发性硬化患者,经倾向评分匹配436例,比较接受与未接受疾病修饰治疗者的临床和MRI结局。治疗组首次复发时间和首次MRI活动时间显著延长,但确认残疾进展、独立于复发活动的进展及继发进展时间无差异。

要点

  • 晚发型多发性硬化患者接受疾病修饰治疗可延长首次复发时间。
  • 治疗组首次MRI活动时间显著延长,提示影像学获益。
  • 残疾进展相关终点在治疗组与未治疗组间无显著差异。

核心结论

  • 疾病修饰治疗对晚发型多发性硬化患者的疾病活动有益,但对残疾进展无显著影响。

研究设计与样本

  • 纳入起病年龄大于55岁且至少有一次随访的复发缓解型多发性硬化患者,共881例符合标准。
  • 采用时间依赖倾向评分匹配比较治疗组与未治疗组,匹配后436例。
  • 治疗组平均随访5.2年,未治疗组平均随访5.0年。

主要发现

  • 治疗组首次复发平均时间为7.0年,未治疗组为5.4年,差异显著(p=0.001)。
  • 治疗组首次MRI活动平均时间为5.9年,未治疗组为5.0年,差异显著(p=0.049)。
  • 确认残疾进展、独立于复发活动的进展及继发进展时间两组无差异(p值分别为0.585、0.442、0.952)。
  • 严重感染发生率比在未治疗组与治疗组比较为0.38(95%CI 0.07-2.10,p=0.265),无显著增加。

关键数值与推荐

  • 起病年龄大于55岁且至少有一次随访的复发缓解型多发性硬化患者纳入分析。
  • 主要结局为匹配后治疗组与未治疗组首次复发时间。
  • 次要结局包括确认残疾进展时间、独立于复发活动的进展时间、继发进展时间、首次MRI活动时间及严重感染发生率。

临床怎么用

  • 对晚发型多发性硬化患者,疾病修饰治疗可考虑用于控制疾病活动如复发和MRI活动。
  • 治疗决策需权衡对残疾进展的有限影响及个体化评估。

局限性

  • 数据收集存在挑战。
  • 两组间存在基线不平衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The therapeutic strategy in patients with late-onset MS (LOMS) remains poorly defined. In this study, we aimed to evaluate both clinical and MRI outcomes between 2 cohorts of patients with relapsing-remitting LOMS treated or not yet treated. METHODS: Patients with relapsing-remitting MS were included for the analysis if disease onset occurred after 55 years and if they had at least one follow-up visit. The primary outcome was time to first relapse between 2 matched groups of patients with LOMS (treated and not yet treated). Secondary outcomes were as follows: (1) time to first confirmed disability progression (CDP), (2) time to first progression independent of relapse activity (PIRA) event, (3) time to secondary progression (SPMS), (4) time to first MRI activity, and (5) serious infection incidence rates (IIRs). For the comparative analyses, we adopted a time-dependent propensity score matching approach. RESULTS: A total of 881 patients fulfilled the inclusion criteria. The mean (SD) age at onset was 59.9 (4.43) years. After applying propensity score matching, 436 patients were matched. The mean (SD) follow-up duration was 5.2 (4.27) years in the treated group and 5.0 (3.86) years in the not-yet-treated group. Mean (SD) time to first relapse was significantly longer in the treated group compared with the not-yet-treated group (7.0 years [0.33] vs 5.4 years [0.33]; p = 0.001). Mean (SD) time to first MRI activity was significantly longer in the treated group (5.9 years [0.33] vs 5.0 years [0.33]; p = 0.049). However, the mean time to CDP, PIRA, or SPMS was not different between the 2 groups (difference = 0.32 years; p = 0.585 for CDP; difference = 0.40 years; p = 0.442 for PIRA; difference = -0.02 years; p = 0.952 for SPMS). No increase in serious IIRs was observed with an incidence rate ratio of 0.38 (95% CI 0.07-2.10, p = 0.265) in the never-treated group compared with the treated one. DISCUSSION: This study demonstrates a beneficial effect of disease-modifying therapy (DMT) on disease activity in patients with LOMS but without significant impact on disability progression. Main limitations are linked to the challenge of data collection and to the baseline imbalances between the 2 groups. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that in patients with LOMS, treatment with DMTs is associated with a longer time to first relapse compared with those not treated with DMTs.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Robin C, Rollot F, Lefort M, et al. Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple Sclerosis. Neurology. 2025. PMID: 40669026. doi:10.1212/WNL.0000000000213744

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。